Coronavirus

Actions

EU: Benefits of J&J vaccine outweigh risks despite possible link to rare clotting condition

Johnson & Johnson COVID-19 Vaccine
Posted at 10:27 AM, Apr 20, 2021
and last updated 2021-04-20 10:45:27-04

The European Medicines Agency (EMA) on Tuesday said that the overall benefit-risk for Johnson & Johnson’s COVID-19 vaccine “remains positive” despite six reports of extremely rare but severe clotting issues in the U.S.

In addition, the EMA — the top medical regulatory body of the European Union — recommended adding a warning label to the vaccines packaging that lists “very rare cases of unusual blood clots with low blood platelets” as a side effect of the vaccine.

The FDA and the CDC recommended a pause in the use of the Johnson & Johnson vaccine last week after a sixth person suffered the rare clotting disorder. About 7 million people in the U.S. safely received a dose of the vaccine before the pause.

Over the weekend, President Joe Biden’s top medical adviser, Dr. Anthony Fauci, said he expects the Johnson & Johnson pause to be lifted later this week.

This story is breaking and will be updated.

Download our streaming app on your favorite device.  Click here for more.

Download our streaming app on your favorite device. Click here for more.